Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition

PARP inhibitor monotherapies are effective to treat patients with breast, ovary, prostate, and pancreatic cancer with BRCA1 mutations, but not to the much more frequent BRCA wild-type cancers. Searching for strategies that would extend the use of PARP inhibitors to BRCA1-proficient tumors, we found...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Res
Main Authors: Luo, Man-Li, Zheng, Fang, Chen, Wenying, Liang, Zhi-Mei, Chandramouly, Gurushankar, Tan, Jianan, Willis, Nicholas A., Chen, Chun-Hau, Taveira, Mateus de Oliveira, Zhou, Xiao Zhen, Lu, Kun Ping, Scully, Ralph, Wulf, Gerburg M., Hu, Hai
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755124/
https://ncbi.nlm.nih.gov/pubmed/32193285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-2739
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker